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Abstract - With 20-80% mortality, neonatal infection caused by herpes simplex virus (HSV) or neonatal herpes is among 
the most severe of all perinatal infections. The majority of neonatal HSV infections are acquired during delivery, although 
in utero and postnatal infections do occur. Primary maternal infection is associated with a high rate of transmission 
(~50%), compared to <3% in infants of women with reactivated disease. Other factors that influence transmission include 
HSV type, premature delivery, etc. Clinical manifestations have been classified into three forms: skin-eye-mouth disease, 
CNS and disseminated disease. The diagnosis of neonatal HSV infection includes the detection of HSV DNA by PCR in 
samples from neonate and mother. The incidence of neonatal herpes differs widely between different countries. In Serbia, 
the data about neonatal herpes incidence are scarce. The results of our pilot study showed that the minimal estimation of 
the national incidence of neonatal herpes is 7.5 per 100 000. Therefore, the set up and implementation of a national neo-
natal herpes surveillance system might provide valuable information for the accurate assessment of disease burden and 
development of an effective prevention strategy in Serbia. 
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INTRODUCTION
Neonatal infection caused by the herpes simplex vi-
rus (HSV) or neonatal herpes was first reported and 
described  in  the  mid-1930s.  Over  the  subsequent 
decades, the spectrum of the disease that HSV can 
cause in the newborn has been well characterized 
and the efficacy of the antiviral therapy in neonatal 
HSV infections has been established. However, even 
today, neonatal herpes is among the most severe of 
all perinatal infections, with 20-80% mortality, pri-
marily due to the fact that 60 to 80% of women who 
deliver an HSV-infected infant have no evidence of 
infection (Kimberlin, 2004a; Malm, 2009).
Virus, transmission and epidemiology
Herpes  simplex  virus  type  1  (HSV-1)  and  type  2 
(HSV-2)  are  ubiquitous,  enveloped  and  double-
stranded DNA viruses, belonging to the family Her-
pesviridae. HSV-1 and HSV-2 are closely related vi-
ruses, although the differences in DNA genome are 
sufficient for type identification and diagnosis. Two 
biological properties of HSV that directly influence 
human disease are latency and neurovirulence. The 
transmission occurs across mucosal membranes and 
nonintact skin by direct contact. After attachment 
to the host epidermal or mucosal cells, viruses are 
transported via axons to the nuclei of sensory neu-518 ALEKSANDRA KNEŽEVIĆ ET AL.
rons. A lifelong latency with reactivation properties 
is  established  which  might  be  influenced  by  host 
or  environmental  factors.  Reactivation  can  result 
in clinically apparent disease (vesicular lesions) or 
clinically inapparent (asymptomatic or subclinical) 
infection (White and Fenner, 1999).
HSV-1 is usually found in the oropharyngeal re-
gion with latency in the trigeminal ganglia, whereas 
HSV-2  is  most  commonly  found  in  the  anogeni-
tal region with latency in the lumbosacral ganglia. 
However,  these  viruses  can  infect  both  areas.  Re-
cently, the increased incidence of HSV-1 as a cause 
of genital herpes has been reported in some devel-
oped countries. This may be explained by sexual be-
havior changes mainly in young adults (Malm, 2009; 
Gardella and Brown, 2011).
HSV infection of the newborn can be acquired 
in utero (intrauterine), intrapartum (perinatal) and 
postpartum  (postnatal).  The  mother  is  the  most 
common source of infection for the first two routes 
of  viral  transmission.  The  vast  majority  (85%)  of 
neonatal HSV infections are acquired during deliv-
ery when the infant comes into direct contact with 
infected maternal secretions in the birth canal. An 
additional 10% of infected neonates acquire the virus 
postnatally (e.g. from someone shedding HSV from 
the mouth who then kisses the baby, from exposure 
to HSV from a breast lesions, or from herpetic whit-
low exposure in the nursery). Intrauterine or con-
genital HSV infection is a rare disorder and accounts 
for 5% of HSV infections in neonates. Intrauterine 
infection may occur either because of ascending in-
fection from the cervix uteri or because of transpla-
cental transmission (Kimberlin, 2007; Anzivino et 
al., 2009).
The most important factors that influence the 
transmission of HSV to the neonate are the type of 
maternal infection (i.e., primary infection, sympto-
matic or asymptomatic reactivation), transmission 
of maternal transplacental antibodies (less mater-
nal-fetal transfer of HSV neutralizing antibodies), 
duration of ruptured membranes in the presence 
of active infection (i.e., longer than 6 h) and the 
use of a fetal scalp monitor at delivery (Kimberlin, 
2004b). 
Primary maternal infection is associated with a 
high rate of transmission (~50%), compared to <3% 
in infants of women with reactivated disease. The 
risk of transmission is increased if the infection oc-
curs late in the third trimester of pregnancy due to 
the lack of an antibody response prior to delivery 
in  late  primary  infection.  However,  most  neona-
tal HSV infections (about 70%) result from expo-
sure to asymptomatic genital HSV infection of the 
mother near delivery (Kimberlin, 2004b; Straface et 
al., 2012). 
The incidence of neonatal herpes varies widely 
between different countries from 8-60 per 100 000 
live births in the USA to 1.6 per 100 000 in the UK 
and Switzerland. These differences are probably due 
to differences in criteria and diagnosis of neonatal 
herpes infections. Numerous studies have reported an 
increased incidence of neonatal herpes over the past 
10 years worldwide. Therefore, in some developed 
countries, surveillance and prevention programs of 
neonatal herpes have been introduced (Malm, 2009; 
Pascual et al., 2011).
In the majority of countries, HSV-2 is associ-
ated with 70% of cases of neonatal herpes. However, 
recent studies reported an increased prevalence of 
neonatal HSV-1 infections, which may be explained 
by an increased prevalence of genital HSV-1 infec-
tions worldwide (Malm, 2009; Pascual et al., 2011; 
Gardella and Brown, 2011). In addition, concomi-
tant neonatal infection with HSV-1 and HSV-2 has 
been reported (Knezevic et al., 2007).
Clinical manifestations
The  clinical  disease  of  neonatal  herpes  usually 
presents in the first 3 weeks of life. The symptoms of 
neonates have been classified into 3 forms of pres-
entation: skin-eye-mouth manifestations (SEM dis-
ease)  without  visceral  or  CNS  involvement,  CNS 
form without other visceral organs being involved, 
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symptoms, disseminated intravascular coagulopathy 
(DIC) and visceral involvement (liver, lungs, adrenal 
glands) with or without CNS symptoms (Kimberlin, 
2004a).
SEM disease accounts for 45% of infants and is 
characterized by vesicular lesions on the skin, eye 
and mouth without CNS or organ-system involve-
ment.  Usually,  this  form  presents  at  10-11  day  of 
age. In the absence of antiviral treatment, 60-70% of 
infants with SEM disease progress to either CNS or 
disseminated disease. With treatment, the outcome 
is good, although these children may have recurrent 
outbreaks  of  cutaneous  herpes  during  childhood 
(Kimberlin, 2004b; Gardella and Brown, 2011).
Infection of the CNS accounts for 30% of infected 
infants. Disease presentation is usually around day 
16-19 of life. Clinical manifestations of this form in-
clude seizures (both focal and generalized), lethargy, 
irritability, tremors, poor feeding and temperature 
instability with or without skin lesions. The mortal-
ity rate is 50% in untreated infants and is the result 
of devastating brain destruction. Although response 
to  therapy  is  generally  good,  moderate  to  severe 
neurological sequelae are evident in 50% of surviv-
ing neonates (Kimberlin, 2007; Gardella and Brown, 
2011).
Disseminated disease is seen in 25% of HSV in-
fected neonates, and mortality in the absence of treat-
ment is high (~85%). Clinical manifestations usually 
appear between 9 and 11 days of age, however the in-
fant may be ill on the first day of life. Neonates com-
monly present with viral sepsis, including respiratory 
collapse, liver failure and DIC. CNS involvement oc-
curs in 60-70% of infants with DISS. If treated, 70% 
of infants survive and about 15% of these neonates 
subsequently suffer from neurological abnormalities 
(Kimberlin, 2004b; Kimberlin, 2007).
Laboratory diagnosis
The laboratory diagnosis of neonatal HSV infection 
includes  demonstration  of  the  virus  (viral  nucleic 
acid) by PCR in samples from the neonate (vesicles, 
nasopharynx, eye, blood and CSF) and mother (cer-
vix uteri, vesicles, and nasopharynx). The viral cul-
ture or immunofluorescence test can be also used 
(Malm, 2009).
The PCR method allows for the rapid diagno-
sis of neonatal herpes, particularly HSV infections 
of the CNS. Not only is it more sensitive than viral 
culture, but it also avoids many problems associated 
with the culture methods (e.g., inadequate quantity 
of specimen, inactivation of the virus through subop-
timal handling and transport delays, etc.). However, 
the interpretation of PCR results, either positive or 
negative, must be correlated with the infant’s clinical 
presentation and disease course in determining their 
ultimate clinical or diagnostic significance (Kimber-
lin, 2004b; Kimberlin, 2007).
Serology or detection of IgM and IgG antibod-
ies from blood and CSF is not of great clinical value 
due to the presence of transplacentally acquired ma-
ternal IgG antibodies. Currently, these methods are 
used  for  complementary  diagnostic  confirmation 
in doubtful cases. Serological investigation of HSV 
type specific IgM and IgG antibodies with an avidity 
test in the mother can be used for the determination 
of the type of maternal infection (primary or reacti-
vating infection) (Enright and Prober, 2002; Malm, 
2009). 
Numerous studies showed that the early recog-
nition and diagnosis of neonatal herpes is crucial 
in decreasing both mortality and the incidence of 
neurological  sequelae  in  surviving  infants.  There-
fore, neonatal HSV infection should be considered 
in the differential diagnosis of acutely ill infants less 
than 1-month-old with mucocutaneous vesicles on 
the skin, eyes and mouth, with seizures and other 
CNS disorders (with negative bacterial cultures after 
48 h and antiepileptic nonresponders) and in febrile 
neonates with signs of sepsis with negative bacterial 
cultures after 48 h associated with hepatitis, DIC, sei-
zures and pneumonia. In these neonates, appropri-
ate laboratory specimens should be taken for HSV 
PCR, and antiviral therapy commenced immediately 
(Kimberlin, 2004b; Fidler et al, 2004).520 ALEKSANDRA KNEŽEVIĆ ET AL.
Treatment and prevention
Antiviral therapy with intravenous acyclovir reduces 
mortality from 85% to 31% among infants with dis-
seminated disease and from 50% to 6% among infants 
with CNS disease. Acyclovir at a dose of 20 mg per 
kilogram of body weight given intravenously every 8 
h for 21 days is recommended for disseminated and 
CNS disease, and the same dose for 14 days is recom-
mended for SEM disease. PCR monitoring for HSV 
DNA should be considered at the end of treatment 
for CNS and disseminated disease. Neonates who re-
main PCR-positive should continue to receive anti-
viral therapy until PCR-negativity is achieved (Kim-
berlin, 2007; Corey and Wald, 2009).
A number of approaches are employed in the 
prevention  of  neonatal  HSV  infection.  Cesarean 
delivery in women with active genital lesions can 
reduce the infant’s risk of acquiring HSV and it is 
recommended when genital herpes lesions or pro-
dromal symptoms are present at the time of delivery 
(Kimberlin, 2007).
However, due to the high rate of undiagnosed 
and asymptomatic HSV infection, the primary goal 
in the prevention of neonatal herpes is the identifi-
cation of the at-risk mother. The determination of 
pregnant women’s HSV serostatus is used to establish 
their susceptibility to the infection during pregnan-
cy. The HSV-seronegative women, as well as, women 
with HSV seropositivity for only one HSV type are 
at risk of acquiring primary infection. In these cases, 
the prevention measurements include education and 
safe-sex counseling. This approach would also iden-
tify women with asymptomatic HSV infection and 
prophylactic administration of acyclovir or valacy-
clovir in the third trimester of pregnancy should be 
provided to all pregnant women with frequent geni-
tal outbreaks (Anzivino et al., 2009; Gardella and 
Brown, 2011). 
Recently, a more direct prevention strategy has 
been introduced. It includes the identification of ne-
onates at risk for HSV exposure at the time of deliv-
ery by sampling genital secretions for HSV PCR of all 
women in labor or prior to labor (in the 36th gesta-
tional week). In this approach, maternal serology is 
used for the determination of the type of viral infec-
tion (primary or recurrent). For those with recurrent 
infection, options could include vaginal delivery with 
acyclovir prophylaxis of the mother and neonate (An-
zivino et al., 2009; Gardella and Brown, 2011). 
Since neonatal herpes can also be acquired post-
natally,  postpartum  women,  family  members  and 
health workers with active herpetic lesions on the 
mouth, skin or breast should take necessary precau-
tionary measures to prevent direct contact with the 
neonate and/or should be excluded from the neona-
tal unit until the lesions are fully healed (Anzivino et 
al., 2009).
NEONATAL HERPES IN SERBIA
In Serbia, the data about neonatal herpes incidence 
are scarce. There are no neonatal herpes or genital 
herpes reporting, surveillance and prevention pro-
grams. The estimation of neonatal herpes burden in 
terms of incidence, mortality and prevalence helps to 
define priorities for preventive, diagnostic and thera-
peutic strategies in order to reduce disease burden. 
Therefore, we conducted a pilot study to evalu-
ate the incidence of neonatal HSV infection in all 
neonates admitted to the Neonatology Department 
at the Mother and Child Health Institute “Dr Vukan 
Čupić” between January 2010 and December 2011. 
During the study period, 1 038 neonates were 
admitted to the hospital. Neonatal herpes was sus-
pected in 35 neonates according to the clinical and 
laboratory parameters, which include the presence 
of mucocutaneous vesicles on skin, eyes and mouth, 
seizures  and  other  CNS  disorders  (with  negative 
bacterial cultures after 48 h and antiepileptic non-
responders) and the presence of febrile syndrome 
with signs of sepsis with negative bacterial cultures 
after 48 h associated with hepatitis, DIC, seizures and 
pneumonia. The diagnosis of neonatal herpes was as-
sessed using type-specific PCR in blood and/or CSF 
and/or vesicle swabs.NEONATAL HERPES IN SERBIA 521
The majority of neonates with suspected neona-
tal HSV infection were with CNS disease (57.1%), 
with disseminated disease in 17.2%, and 25.7% had 
other symptoms indicative for neonatal herpes. There 
were no suspected neonates with SEM disease. Out 
of the 35 neonates with suspected neonatal herpes, 
11 were positive. Nine were HSV-1 positive (81.8%). 
The  most  of  positive  neonates  had  CNS  infection 
(63.6%). Overall incidence in this study was 1.06 % 
(11/1038).
Extrapolating from the obtained data and applied 
to approximately 70 000 annual live births in Serbia, 
the minimal estimation of the national incidence of 
neonatal herpes is 7.5 per 100 000 live births. This 
finding is higher compared to the reported data of 
neonatal herpes incidence in other European coun-
tries. 
In conclusion, neonatal herpes has an important 
role in morbidity and mortality of newborns in Ser-
bia. Therefore, the set-up and implementation of a 
national neonatal herpes surveillance system might 
provide valuable information for the accurate assess-
ment of disease burden and development of effective 
prevention strategy in Serbia. 
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